Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2018
At a glance
- Drugs Sunitinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 17 Jun 2016 Planned primary completion date changed from 1 May 2016 to 1 Dec 2016.
- 08 Dec 2015 Planned primary completion date changed from 1 Dec 2015 to 1 May 2016, according to ClinicalTrials.gov record.